Last reviewed · How we verify
TIV-HA Vaccine formulation 1 at low dose — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
TIV-HA Vaccine formulation 1 at low dose (TIV-HA Vaccine formulation 1 at low dose) — Sanofi.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TIV-HA Vaccine formulation 1 at low dose TARGET | TIV-HA Vaccine formulation 1 at low dose | Sanofi | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TIV-HA Vaccine formulation 1 at low dose CI watch — RSS
- TIV-HA Vaccine formulation 1 at low dose CI watch — Atom
- TIV-HA Vaccine formulation 1 at low dose CI watch — JSON
- TIV-HA Vaccine formulation 1 at low dose alone — RSS
Cite this brief
Drug Landscape (2026). TIV-HA Vaccine formulation 1 at low dose — Competitive Intelligence Brief. https://druglandscape.com/ci/tiv-ha-vaccine-formulation-1-at-low-dose. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab